Available from FDA Website: Benadjaound Y, Kindelan K, Krill L
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity
The medication is initiated at 2.5 mg once weekly for 4 weeks, then increased by 2.5 mg increments at 4-week intervals as tolerated, with typical maintenance doses of 5 mg, 10 mg, or 15 mg
What to expect during the transition The first 2-4 weeks after switching often involve a temporary reduction in appetite suppression
If you are serious about getting your dosing right, SeekPeptides was built for exactly that purpose
Bonora BM, Russo G, Leonetti F, et al